iSchemaView, the worldwide leader in advanced imaging for stroke care and research, is proud to announce that iSchemaView co-founder Dr. Gregory Albers has received the highly respected Distinguished Clinical Research Achievement Award, presented by the Clinical Research Forum.
The Distinguished Clinical Research Achievement Awards are presented to the top two studies that show creativity, innovation, or a novel approach that demonstrates an immediate impact on the health and well-being of patients.
In the DEFUSE 3 study, Dr. Albers and his team used iSchemaViews RAPID„¢ advanced medical imaging platform, exclusively, to identify stroke patients who continue to have salvageable brain tissue many hours after stroke onset. By identifying patients who are most likely to benefit from stroke therapies, the DEFUSE 3 study is credited with accelerating the development and testing of new therapeutic options, as well as enabling hospitals to offer life-saving stroke therapies to many patients who arrive after the previous standard six-hour treatment window has elapsed.
Dr. Albers is the Coyote Foundation professor of neurology and neurological sciences, and professor, by courtesy, of neurosurgery at the Stanford University Medical Center. He is also director of the Stanford Stroke Center. Dr. Albers primary research focus is the diagnosis, management and prevention of ischemic stroke. He was instrumental in the development of RAPID, a medical imaging platform that allows physicians to identify stroke patients who have salvageable brain tissue. Due to the findings of DEFUSE 3 and other groundbreaking stroke studies that also employed RAPID, the American Heart Association and American Stroke Association changed their treatment guidelines for thrombectomy from six hours after onset to up to 24 hours after onset for patients with salvageable brain tissue.
Following the awards ceremony, Dr. Albers will present the results of the DEFUSE 3 study to members of Congress and discuss the critical role of federal funding for clinical research.
My team and I are honored to receive the Distinguished Clinical Research Achievement Award, said Dr. Albers. It is incredibly gratifying to know that our findings have helped change the landscape for the diagnosis and treatment of ischemic stroke, leading to more patients being addressed, reducing disabilities and saving lives.
iSchemaView is the worldwide leader in advanced imaging for stroke. Installed in over 1,000 stroke centers, iSchemaViews RAPID (automated CTP, MRI, CTA and ASPECTS), with enhanced AI framework, is the most advanced stroke imaging platform. In clinical trials, RAPID has been shown to aid in the selection of patients in early and late-window stroke trials, including SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3 and EXTEND. In addition to achieving the best clinical outcomes and largest treatment effects ever obtained, these landmark studies led to new American Heart Association and American Stroke Association guidelines and have dramatically altered the management of acute stroke around the world. For more information, visit www.RAPID.ai
About the Top Ten Clinical Research Achievement Awards
Recognizing the need to celebrate our nations clinical research accomplishments that involve both innovation and impact on human disease, the Clinical Research Forum conducts an annual competition to determine the ten outstanding research accomplishments in the United States. These major research advances represent a portion of the annual return on the nations investment in the health and future welfare of its citizens.
About the Clinical Research Forum
The mission of the Clinical Research Forum is to provide leadership to the national and clinical translational research enterprise and promote understanding and support for clinical research and its impact on health and healthcare. For more information, visit www.clinicalresearchforum.org.